Skip to main content
Top

Breast Cancer Research and Treatment

Issue 2/2004

Content (9 Articles)

Response to fulvestrant in heavily pretreated postmenopausal women:a single-center experience

Sandra Franco, Alejandra Perez, Elizabeth Tan-chiu, Cynthia Frankel, Charles L. Vogel

Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis

Harry M. Lightfoot, Amy Lark, Chad A. Livasy, Dominic T. Moore, David Cowan, Lynn Dressler, Rolf J. Craven, William G. Cance

Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program

J. Y. Pierga, P. Fumoleau, Y. Brewer, L. Zelek, D. Martin, F. L. Turpin, M. J. Goudier, M. Gil-delgado, J. L. Baticle, M. Namer, P. Chollet, W. Sutherland, J. C. Barats

Genomic patterns of allelic imbalance in disease free tissue adjacent to primary breast carcinomas

Darrell L. Ellsworth, Rachel E. Ellsworth, Brad Love, Brenda Deyarmin, Susan M. Lubert, Vimal Mittal, Craig D. Shriver

Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India

Suresh Hedau, Neeraj Jain, Syed A. Husain, Ashish K. Mandal, Gibanananda Ray, M. Shahid, Ravi Kant, Vishal Gupta, Nootan K. Shukla, Suryanarayan S. V. Deo, Bhudev C. Das

A population-based study of the impact of delaying radiotherapy after conservative surgery for breast cancer

Nicole Hébert-croteau, Carolyn R. Freeman, Jean Latreille, Michèle Rivard, Jacques Brisson

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine